Novartis' Scemblix Receives EMA Approval as a Third-Line Treatment for Leukemia
Innovative Mechanism of Action and EMA Approval Rationale
Novartis' Scemblix (asciminib), a treatment for chronic myeloid leukemia (CML), has received marketing authorization from the European Medicines Agency (EMA) on August 25, 2022. This novel drug is the first STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor that selectively binds to the myristoyl pocket of the BCR-ABL1 protein, unlike existing targeted therapies. It can overcome resistance caused by mutations in the ATP-binding site, where first- and second-generation treatments bind, offering an innovative alternative for patients. This unique mechanism of action provides new treatment options for patients who have received two or more tyrosine kinase inhibitors (TKIs).
Implications of the Phase 3 ASCEMBL Data
This European approval is based on the results of the Phase 3 ASCEMBL study, which compared Scemblix with bosutinib in patients with CML who had previously received treatment. The results showed that at week 24, the major molecular response (MMR) rate was 25.5% in the Scemblix group, nearly double the 13.2% in the bosutinib group. Long-term follow-up at week 96 also showed that Scemblix had an MMR rate of 37.6%, demonstrating sustained efficacy compared with the 15.8% in the bosutinib group. The U.S. FDA approved the drug in October 2021 without holding an advisory committee meeting, and Japan's PMDA granted marketing authorization in March 2022.
Changes in the Competitive Landscape of the Leukemia Treatment Market
Scemblix addresses the unmet needs of patients who have developed resistance to or discontinued treatment with existing standard-of-care (SoC) treatments such as Gleevec or Tasigna. In particular, it has shown excellent treatment response in patients with the T315I mutation, a difficult-to-treat mutation, and has a better safety profile than existing treatments such as bosutinib or Iclusig. Its low toxicity improves patient compliance, and with the completion of pricing and reimbursement negotiations in Europe, it is rapidly establishing its position in the third-line treatment market.
Prospects for Blockbuster Status and Financial Growth
With its successful market launch, Scemblix is expected to exceed $1 billion in annual sales in 2025, achieving blockbuster status. Novartis has raised its peak sales forecast from $3 billion to over $4 billion, based on the potential for first-line (1L) market entry through the ongoing Phase 3 ASC4FIRST trial. If it enters the first-line market, the target patient population will increase by approximately fourfold, making it a key driver of the company's growth.
Novartis' Scemblix demonstrated a 24-week major molecular response rate that was twice as high as that of the comparator, bosutinib (25.5% vs. 13.2%), in the Phase 3 ASCEMBL trial, and is expected to exceed $1 billion in annual sales in 2025, achieving blockbuster status. Following approvals from the FDA (October 2021) and PMDA (March 2022), this EMA approval is expected to solidify its position in the global third-line treatment market, replacing bosutinib and Iclusig. Furthermore, with the ongoing Phase 3 ASC4FIRST trial targeting new patients, its entry into the first-line market is expected to expand the patient pool by fourfold, making the company's stated peak sales target of $4 billion achievable. As the first STAMP mechanism-based anticancer drug that targets the myristoyl pocket rather than the ATP-binding site, it has long-term significance in establishing a paradigm shift in anticancer drug research and development through unique target design to overcome resistance.
Source: EMA (ema)